TEVA vs UTHR
Teva Pharmaceutical Industries Limited vs United Therapeutics — AI-powered side-by-side comparison
TEVA
Teva Pharmaceutical Industries Limited
55
Watch
VS
UTHR
United Therapeutics
72
Buy
| Metric | TEVA | UTHR |
|---|
| AI Score |
55
|
72
|
| Price |
$36.49
|
$514.89
|
| P/E Ratio |
57.19×
|
17.05×
|
| ROE |
17.8%
|
18.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
52.5%
|
86.1%
|
| Debt / Equity |
2.16×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
77.8
|
52.2
|
| Beta |
0.864
|
0.564
|
| Expected Upside |
—
|
+6.4%
|
AI Committee View
Current Innellis committee reasoning for TEVA versus UTHR.
UTHR leads by 17 points.
UTHR scores 72/100 (Buy) versus TEVA at 55/100 (Watch).
TEVA Committee View
50% agreement
6 analysts
The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.63 across 21 articles, 14d). Value Analyst remains cautious — p/e of 57.5 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 57.5 is expensive by classic value standards — Value
- Price-to-book of 4.9x prices in significant intangible value — Value
- Debt-to-equity of 2.12 adds balance-sheet risk to the value case — Value
UTHR Committee View
80% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 13.5% downside vs 6.4% upside.